Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty
Vascular Pharmacology · 2026
DOI: 10.1016/j.vph.2026.107677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2026. Verfasst von Alice Nerini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, 50134 Firenze, Italy. Hauptthemen laut MEDLINE: Aspirin, Fibrin, Fibrinogen, Platelet Aggregation Inhibitors. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fibrin clot architecture is increasingly recognized as a determinant of thrombotic phenotype and a potentially modifiable endpoint in vascular pharmacology. Aspirin is established as an antiplatelet agent through irreversible cyclooxygenase-1 acetylation and thromboxane A₂ suppression. Beyond this canonical pathway, aspirin has been proposed to modulate fibrin clot properties through nonenzymatic Nε-lysine acetylation of fibrinogen. Experimental studies in purified, recombinant, and selected ex vivo systems suggest effects on fibrin polymerization, factor XIIIa-dependent cross-linking, clot permeability, viscoelasticity, and fibrinolysis, with aspirin-sensitive lysines identified across fibrinogen chains. However, clinical relevance remains uncertain. At clinically relevant exposure, fibrinogen acetylation appears generally low, and contemporary low-dose aspirin does not consistently increase acetylation or modify clot phenotype despite effective platelet thromboxane suppression. Disease-related modifications, including glycation, carbamylation, oxidation, and nitration, may further reshape fibrin structure and influence aspirin responsiveness. This review examines the biochemical rationale, experimental evidence, disease-context dependency, and limitations of aspirin-mediated fibrinogen acetylation as a proposed extra-platelet mechanism. Its biological significance will require quantitative evidence of site occupancy, residue-specific function, physiological aspirin exposure, standardized clot assays, and integration with disease-specific modifiers of fibrin phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, 50134 Firenze, Italy.
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Firenze, 50134 Firenze, Italy. Electronic address: claudia.fiorillo@unifi.it.
Zitieren
APA
Nerini, A., Nencini, F., Borghi, S., Giurranna, E., Taddei, N., Fiorillo, C., & Becatti, M. (2026). Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2026.107677
Vancouver
Nerini A, Nencini F, Borghi S, Giurranna E, Taddei N, Fiorillo C, et al. Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty. Vascular Pharmacology. 2026. doi:10.1016/j.vph.2026.107677
BibTeX
@article{Nerini2026,
author = {Nerini, Alice and Nencini, Francesca and Borghi, Serena and Giurranna, Elvira and Taddei, Niccolò and Fiorillo, Claudia and Becatti, Matteo},
title = {Aspirin and fibrin clot modulation in vascular pharmacology: Fibrinogen acetylation, disease context, and translational uncertainty},
journal = {Vascular Pharmacology},
year = {2026},
doi = {10.1016/j.vph.2026.107677}
}
EUVIMED